Jaguar Health Boosts Public Float to Regain Nasdaq Compliance

Jaguar Animal Health ( (JAGX) ) has shared an update.

On May 1, 2026, Jaguar Health disclosed that a 1-for-35 reverse stock split, effective April 30, 2026, had reduced its publicly held common shares to about 401,226, putting the company below Nasdaq’s 500,000-share minimum and leaving it non-compliant with both the public float and $1.00 minimum bid price requirements. After certain third-party investors exercised pre-funded warrants on May 4, 2026, Jaguar’s outstanding and publicly held shares increased to 513,974 and 513,939 respectively, and the company is now awaiting formal confirmation from Nasdaq staff that it has regained compliance with the public float standard, a key step toward preserving its Nasdaq listing.

Spark’s Take on JAGX Stock

According to Spark, TipRanks’ AI Analyst, JAGX is a Underperform.

The score is held down primarily by stressed fundamentals (large ongoing losses and a weakened capital structure) and very bearish technicals (well below major moving averages with negative MACD). Corporate actions show some balance-sheet support and debt relief, but ongoing Nasdaq compliance/delisting risk and the lack of meaningful valuation support (negative P/E, no dividend yield provided) keep the overall risk profile very high.

To see Spark’s full report on JAGX stock, click here.

More about Jaguar Animal Health

Jaguar Health, Inc. is a pharmaceutical company focused on developing and commercializing prescription therapies, with its common stock listed on the Nasdaq Capital Market. The company’s equity structure and compliance with Nasdaq’s listing standards, including minimum bid price and publicly held share thresholds, are critical to maintaining its exchange listing and access to public capital markets.

Average Trading Volume: 16,181

Technical Sentiment Signal: Sell

Current Market Cap: $2.68M

For detailed information about JAGX stock, go to TipRanks’ Stock Analysis page.